Utility of genetic testing for prenatal presentations of hypophosphatasia

Mol Genet Metab. 2021 Mar;132(3):198-203. doi: 10.1016/j.ymgme.2021.01.009. Epub 2021 Jan 27.

Abstract

Hypophosphatasia (HPP) is a rare inherited disease affecting bone and dental mineralization due to loss-of-function mutations in the ALPL gene encoding the tissue nonspecific alkaline phosphatase (TNSALP). Prenatal benign HPP (PB HPP) is a rare form of HPP characterized by in utero skeletal manifestations that progressively improve during pregnancy but often still leave symptoms after birth. Because the prenatal context limits the diagnostic tools, the main difficulty for clinicians is to distinguish PB HPP from perinatal lethal HPP, the most severe form of HPP. We previously attempted to improve genotype phenotype correlation with the help of a new classification of variants based on functional testing. Among 46 perinatal cases detected in utero or in the neonatal period for whose ALPL variants could be classified, imaging alone was thought to clearly diagnose severe lethal HPP in 35 cases, while in 11 cases, imaging abnormalities could not distinguish between perinatal lethal and BP HPP. We show here that our classification of ALPL variants may improve the ability to distinguish between perinatal lethal and PB HPP in utero.

Keywords: Genetic counseling; Hypophosphatasia; Prenatal benign hypophosphatasia; Prenatal context.

MeSH terms

  • Alkaline Phosphatase / genetics*
  • Alleles
  • Female
  • Fetus / pathology
  • Genetic Association Studies
  • Genetic Testing*
  • Humans
  • Hypophosphatasia / diagnosis*
  • Hypophosphatasia / diagnostic imaging
  • Hypophosphatasia / genetics
  • Hypophosphatasia / pathology
  • Male
  • Mutation / genetics
  • Pregnancy
  • Prenatal Diagnosis*

Substances

  • ALPL protein, human
  • Alkaline Phosphatase